Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib plus Gemcitabine in Advanced Pancreatic Cancer
NCT02024633Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Dec 2013
- Primary completion
- Dec 2015
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in pancreatic adenocarcinoma (PDAC), sponsored by Betta Pharmaceuticals. Primary endpoint: Number of patients who suffer adverse events at 24 months. Status: unknown.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02024633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02024633.